All News Aptose Biosciences Inc.

Equities

APS

CA03835T3091

Market Closed - Toronto S.E. Other stock markets 12:36:06 26/06/2024 am IST			5-day change	1st Jan Change
1.015 ^CAD	-1.46%		-16.12%	-69.70%

18/06	Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call
14/06	Aptose Biosciences Inc. Presents Tuspetinib Clinical and Preclinical Findings At European Hematology Association 2024 Hybrid Congress	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aptose Announces Results from Annual and Special Meeting of Shareholders	19/06	AQ
Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call	18/06
Aptose Biosciences : 2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)	14/06	PU
Aptose Biosciences : 2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax	14/06	PU
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress	14/06	AQ
Aptose Biosciences Inc. Presents Tuspetinib Clinical and Preclinical Findings At European Hematology Association 2024 Hybrid Congress	14/06	CI
HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	11/06	MT
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04/06	MT
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	MT
Aptose Biosciences Brief: Announcing US$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	MT
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	AQ
APTE BIOS : Earnings Presentation	15/05	PU
APTE BIOS : Aptose 1Q Earnings Presentation	15/05	PU
Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses	15/05	MT
Aptose Biosciences: Q1 Earnings Snapshot	15/05	AQ
Aptose Biosciences Brief: Also Notes TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML	15/05	MT
Aptose Biosciences Brief: Notes TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to FDA During Q1 and is Now Being Activated at Clinical Sites	15/05	MT
Aptose Biosciences Brief: Q1 Net Loss per share, Basic and diluted US$(0.73)	15/05	MT
Aptose Reports Results for the First Quarter 2024	15/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Aptose Biosciences Inc.

Equities

APS

CA03835T3091

All News

Filters